Claims

1. A compound of formula (I)



(I)

wherein
R represents halogen or C_{1-4} alkyl;
R_1 represents hydrogen or C_{1-4} alkyl;
R_2 represents hydrogen , C_{1-4} alkyl;
R_3 represents hydrogen, C_{1-4} alkyl ;
R_4 represents trifluoromethyl, C_{1-4} alkyl, C_{1-4} alkoxy, trifluoromethoxy or halogen;
R_5 represents hydrogen, C_{1-4} alkyl, C_{3-7} cycloalkyl, $C(O)R_6$ or $S(O)_2R_6$;
R_6 represents C_{1-4} alkyl or C_{3-7} cycloalkyl;
m is zero or an integer from 1 to 3;
n is an integer from 1 to 3;
p is an integer from 1 to 2;
X and Y are independently C(O) or CH_2;
provided that
i) X and Y are not both C(O) and
ii) when X and Y are both CH_2 and p is 1, R_5 is not hydrogen , C_{1-4} alkyl or $C(O)R_6$;
and pharmaceutically acceptable salts and solvates thereof.

2. A compound as claimed in claim 1 wherein R is a halogen (e.g. fluorine) and/or a C_{1-4} alkyl (e.g. methyl) group and m is preferably zero or an integer from 1 to 2.

3. A compound as claimed in claim 1 or 2 wherein R_1 is a methyl group.

4. A compound as claimed in any claims from 1 to 3 wherein R_2 is a hydrogen atom or a methyl group.

5. A compound as claimed in any claims from 1 to 4 wherein R_3 is a hydrogen atom or a methyl group.

6. A compound as claimed in any claims from 1 to 5 wherein R_4 is a trifluoromethyl group or halogen (i.e chlorine).

7. A compound as claimed in any claims from 1 to 6 wherein R_5 is hydrogen, metyl, cyclopropyl , $C(O)CH_3$ or $S(O)_2CH_3$.

8. A compound as claimed in any claims from 1 to 7 wherein p is 1.

9. A compound as claimed in any claims from 1 to 8 wherein R is at the 2 and/or 4 position in the phenyl ring .

10. A compound as claimed in any claims from 1 to 9 wherein n is 2 and the groups R_4 are at the 3 and 5 position in the phenyl ring.

11. A compound as claimed in any claims from 1 to 10 wherein
R is fluorine and/or C_{1-4} alkyl (e.g. methyl);
R_1 is a methyl group;
R_2 is a hydrogen atom or a methyl group;
R_3 is a hydrogen atom or a methyl group;
R_4 is trifluoromethyl;
R_5 is hydrogen , metyl, cyclopropyl , $C(O)CH_3$ or $S(O)_2CH_3$;
m is 1 or 2;
n is 2;
p is 1.

12 A compound selected from
2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(R)-(3-oxo-piperazin-1-yl-)-piperidine-1-carboxylic acid, (3,5-bis-trifluoromethyl-benzyl)-methylamide;
2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-(3-oxo-piperazin-1-yl-)-piperidine-1-carboxylic acid, (3,5-bis-trifluoromethyl-benzyl)-methylamide;
2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(R)-(4-methyl-3-oxo-piperazin-1-yl-)-piperidine-1-carboxylic acid, 1-(3,5-bis-trifluoromethyl-benzyl)-methylamide;
2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-(4-methyl-3-oxo-piperazin-1-yl-)-piperidine-1-carboxylic acid, 1-(3,5-bis-trifluoromethyl-benzyl)-methylamide;
2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-(4-methyl-3-oxo-piperazin-1-yl)-piperidine-1-carboxylic acid, [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide;
2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(R)-(2-oxo-piperazin-1-yl)-piperidine-1-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methylamide;
2-(4-Fluoro-2-methyl-phenyl)-4-(S)-(2-oxo-piperazin-1-yl)-piperidine-1-carboxylic acid, (3,5-bis-trifluoromethyl-benzyl)-methylamide;
2-(4-Fluoro-2-methyl-phenyl)-4-(S)-(2-oxo-piperazin-1-yl)-piperidine-1-carboxylic acid, (3,5-bis-trifluoromethyl-benzyl)-methylamide;
2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-(2-oxo-4-methyl-piperazin-1-yl)-piperidine-1-carboxylic acid, (3,5-bis-trifluoromethyl-benzyl)-methylamide;
2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-(4-methyl-2-oxo-piperazin-1-yl)-piperidine-1-carboxylic acid, [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide;

2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-(4-methyl-2-oxo-piperazin-1-yl)-piperidine-1-carboxilic acid, [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide;
2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(R)-(4-cyclopropyl-3-oxo-piperazin-1-yl-)-piperidine-1-carboxylic acid, 1-(3,5-bis-trifluoromethyl-benzyl)-methylamide;
2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-(4-cyclopropyl-3-oxo-piperazin-1-yl-)-piperidine-1-carboxylic acid, 1-(3,5-bis-trifluoromethyl-benzyl)-methylamide;
2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-(1-methanesulfonyl-piperazin-1-yl)-piperidine-1-carboxylic acid, 1-(3,5-bis-trifluoromethyl-benzyl)-methylamide;
2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-(1-methanesulfonyl-piperazin-1-yl)-piperidine-1-carboxylic acid, 1-[(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide;
and pharmaceutically acceptable salts (e.g. hydrochloride, methanesulphonate, sulphate, p-toluensulphonate) and solvates thereof.

13. A compound as claimed in any claims from 1 to 12 for use in therapy.

14. The use of a compound as claimed in any claims from 1 to 12 in the preparation of a medicament for use in the treatment of conditions mediated by tachykinins, including substance P and other neurokinins.

15. The use of a compound as claimed in any claims from 1 to 12 in the treatment of conditions mediated by tachykinins, including substance P and other neurokinins.

16. A pharmaceutical composition comprising a compound as claimed in any claims from 1 to 12 in a mixture with one or more pharmaceutically acceptable carriers or excipients.

17. A method for the treatment of a mammal, including man, in particular in the treatment of conditions mediated by tachykinins, including substance P and other neurokinins, comprising administration of an effective amount of a compound as claimed in any claims from 1 to 12.

18. A process for the preparation of a compound as claimed in any claims from 1 to 12, which comprises
a) reacting a compound of formula (II),



(II)



(III)

with compound of formula(III) in the presence of a suitable metal reducing agent to prepare a compound of formula (I), wherein X is CH_2 or C(O) and Y is CH_2;

b) cyclisation of a compound of formula (VII),



(VII)

wherein P is a nitrogen protecting group and L is a suitable leaving group, to obtain compounds of formula (I) wherein Y is C(O);

followed where necessary or desired by one or more of the following steps:

i) removal of any protecting group;

ii) isolation of the compound as a salt or a solvate thereof;

iii) separation of a compound of formula(I) or derivative thereof into the enantiomers thereof.